Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.
MMWR Recomm Rep. 2024 Aug 8;73(3):1-77. doi: 10.15585/mmwr.rr7303a1.
The 2024 U.S. Selected Practice Recommendations for Contraceptive Use (U.S. SPR) addresses a selected group of common, yet sometimes complex, issues regarding initiation and use of specific contraceptive methods. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during January 25-27, 2023. The information in this report replaces the 2016 U.S. SPR (CDC. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR 2016;65[No. RR-4]:1-66). Notable updates include 1) updated recommendations for provision of medications for intrauterine device placement, 2) updated recommendations for bleeding irregularities during implant use, 3) new recommendations for testosterone use and risk for pregnancy, and 4) new recommendations for self-administration of injectable contraception. The recommendations in this report are intended to serve as a source of evidence-based clinical practice guidance for health care providers. The goals of these recommendations are to remove unnecessary medical barriers to accessing and using contraception and to support the provision of person-centered contraceptive counseling and services in a noncoercive manner. Health care providers should always consider the individual clinical circumstances of each person seeking contraceptive services. This report is not intended to be a substitute for professional medical advice for individual patients; when needed, patients should seek advice from their health care providers about contraceptive use.
2024 年美国避孕选择实践推荐(U.S. SPR)针对特定避孕方法的启动和使用方面的一些常见但有时复杂的问题提供了建议。这些建议是由美国疾病控制与预防中心(CDC)在对科学证据进行审查并于 2023 年 1 月 25 日至 27 日在佐治亚州亚特兰大举行的全国专家会议之后更新的。本报告中的信息取代了 2016 年美国 SPR(CDC. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR 2016;65[No. RR-4]:1-66)。值得注意的更新包括:1)为宫内节育器放置提供药物的建议更新;2)使用植入物期间出血异常的建议更新;3)关于睾丸素使用和怀孕风险的新建议;4)自我管理注射避孕的新建议。本报告中的建议旨在为医疗保健提供者提供循证临床实践指南。这些建议的目的是消除获得和使用避孕措施的不必要的医疗障碍,并以非强制的方式支持提供以个人为中心的避孕咨询和服务。医疗保健提供者应始终考虑每个寻求避孕服务的人的个人临床情况。本报告无意替代针对个别患者的专业医疗建议;如有需要,患者应向医疗保健提供者咨询避孕使用问题。